Mark Stanley Berger - 27 Feb 2026 Form 4 Insider Report for Genprex, Inc. (GNPX)

Reporting relationship: Chief Medical Officer
Issuer ticker: GNPX
Reported as of: 27 Feb 2026
Net transaction value: -$14,336
SEC form: 4
Accepted by SEC: 27 Feb 2026, 18:34:18 UTC
Prior SEC filing: 23 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Mark Berger

Key filing fact

Mark Stanley Berger filed Form 4 for Genprex, Inc. (GNPX) on 27 Feb 2026.

Key facts

This page summarizes Mark Stanley Berger's Form 4 filing for Genprex, Inc. (GNPX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Feb 2026, 18:34.

Change

Previous filing in this sequence was filed on 23 Dec 2025.
Current net transaction value: -$14,336.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001700283 Primary reporting owner

Berger Mark Stanley

Relationship: Chief Medical Officer
Address: 3300 BEE CAVE ROAD, #650-227, AUSTIN
Signature: /s/ Mark Berger
Signature date: 27 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GNPX transaction

Common Stock

Tax liability

Transaction value: $14,336
Shares: -7,168
Change %: -25%
Price: $2.00
Shares after: 21,692
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares withheld on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs") previously granted under the Genprex, Inc. 2018 Equity Incentive Plan (as amended and restated effective June 30, 2025).